EGFR and neoplasm: Interestingly, fusing the scFv anti-EGFR to single-chain TRAIL (scTRAIL, see Figure 7), instead of a single monomer of TRAIL, further increased the tumor killing efficiency of the scFv-TRAIL variant by 10-fold [175], highlighting the importance of TRAIL valency for its efficacy.